Imugene Limited (ASX:IMU)

Imugene Limited, a clinical-stage immuno-oncology company, released its Quarterly Activities and Cash Flow Report for the period ending 31 December 2025. Key highlights include significant progress in the Azer-cel Phase 1b clinical trial for relapsed/refractory diffuse large B-cell lymphoma, achieving an 82% overall response rate. The trial results exceeded expectations with 14 out of 17 patients showing responses, supporting the potential of Azer-cel as a therapeutic option for patients with limited treatment alternatives. The company also reported strong performance in a CAR T naïve cohort, with an 83% overall response rate. Financially, Imugene reported $14.1 million in cash and cash equivalents at the end of the quarter. The company is actively managing its cash position and expects operating costs to reduce significantly compared to the previous year. Strategic collaborations, such as with JW Therapeutics on the onCARlytics program, are also advancing. The company is focused on streamlining its R&D program and maintaining a lean operation with reduced headcount, ensuring the continued development of its immunotherapy programs.